News | July 21, 2025
Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
The new Zigly center features and offers comprehensive veterinary services
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
This marks the fourth acquisition by Corona Remedies from multinational corporations
The campaign celebrates radiant, healthy skin that shines naturally, empowering women to step forward with confidence in every walk of life.
Godavari Biorefineries receives patent from CNIPA
Subscribe To Our Newsletter & Stay Updated
